Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 168

1.

Process Dissociation Analyses of Memory Changes in Healthy Aging, Preclinical, and Very Mild Alzheimer Disease: Evidence for Isolated Recollection Deficits.

Millar PR, Balota DA, Maddox GB, Duchek JM, Aschenbrenner AJ, Fagan AM, Benzinger TL, Morris JC.

Neuropsychology. 2017 Feb 16. doi: 10.1037/neu0000352. [Epub ahead of print]

PMID:
28206782
2.

In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.

Zhao Y, Raichle ME, Wen J, Benzinger TL, Fagan AM, Hassenstab J, Vlassenko AG, Luo J, Cairns NJ, Christensen JJ, Morris JC, Yablonskiy DA.

Neuroimage. 2016 Dec 15;148:296-304. doi: 10.1016/j.neuroimage.2016.12.026. [Epub ahead of print]

PMID:
27989773
3.

Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.

Suárez-Calvet M, Araque Caballero MÁ, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C; Dominantly Inherited Alzheimer Network..

Sci Transl Med. 2016 Dec 14;8(369):369ra178.

PMID:
27974666
4.

Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.

Deming Y, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Bertelsen S, Huang KL, Sutphen CL, Tarawneh R, Fagan AM, Holtzman DM, Morris JC, Goate AM, Dougherty JD, Cruchaga C.

BMC Neurol. 2016 Nov 10;16(1):217.

5.

Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.

Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, Kornhuber J, Morris JC, Fagan AM.

J Alzheimers Dis. 2017;55(2):813-822.

6.

Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).

Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, Fagan AM, Goate A, Marcus DS, Xiong C, Allegri RF, Chhatwal JP, Danek A, Farlow MR, Fox NC, Ghetti B, Graff-Radford NR, Laske C, Martins RN, Masters CL, Mayeux RP, Ringman JM, Rossor MN, Salloway SP, Schofield PR, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN)..

Lancet Neurol. 2016 Dec;15(13):1317-1325. doi: 10.1016/S1474-4422(16)30229-0.

PMID:
27777020
7.

Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.

Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TL, Fagan AM, Morris JC, Roe CM.

Am J Geriatr Psychiatry. 2016 Nov;24(11):1095-1104. doi: 10.1016/j.jagp.2016.04.004.

PMID:
27426238
8.

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.

Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network..

Alzheimers Dement. 2017 Jan;13(1):8-19. doi: 10.1016/j.jalz.2016.07.005.

PMID:
27583651
9.

Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.

Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL.

JAMA Neurol. 2016 Oct 1;73(10):1192-1200. doi: 10.1001/jamaneurol.2016.2642.

PMID:
27548756
10.

BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.

Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, McDade E, Ringman JM, Rossor M, Salloway S, Schofield PR, Holtzman DM, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network..

Brain. 2016 Oct;139(Pt 10):2766-2777.

PMID:
27521573
11.

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM.

JAMA Neurol. 2016 Sep 1;73(9):1070-7. doi: 10.1001/jamaneurol.2016.2078.

PMID:
27454922
12.

Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.

Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, Holtzman DM, Benzinger TL, Morris JC, Fagan AM.

Ann Neurol. 2016 Sep;80(3):379-87. doi: 10.1002/ana.24719.

PMID:
27398953
13.

Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease.

Muenchhoff J, Poljak A, Thalamuthu A, Gupta VB, Chatterjee P, Raftery M, Masters CL, Morris JC, Bateman RJ, Fagan AM, Martins RN, Sachdev PS.

Sci Rep. 2016 Jul 6;6:29078. doi: 10.1038/srep29078.

14.

NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers.

Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, Fagan AM, Benzinger TL.

Neurobiol Aging. 2016 Aug;44:1-8. doi: 10.1016/j.neurobiolaging.2016.03.025.

PMID:
27318129
15.

The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.

Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, Aldea P, McConathy J, Holtzman DM, Cairns NJ, Morris JC, Fagan AM, Ances BM, Benzinger TL.

Brain. 2016 Aug;139(Pt 8):2249-60. doi: 10.1093/brain/aww139.

PMID:
27286736
16.

Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning.

Hassenstab J, Chasse R, Grabow P, Benzinger TL, Fagan AM, Xiong C, Jasielec M, Grant E, Morris JC.

Neurobiol Aging. 2016 Jul;43:23-33. doi: 10.1016/j.neurobiolaging.2016.03.014.

PMID:
27255812
17.

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.

Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TL, Ances BM.

Sci Transl Med. 2016 May 11;8(338):338ra66. doi: 10.1126/scitranslmed.aaf2362.

PMID:
27169802
18.

Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid.

Ju YE, Finn MB, Sutphen CL, Herries EM, Jerome GM, Ladenson JH, Crimmins DL, Fagan AM, Holtzman DM.

Ann Neurol. 2016 Jul;80(1):154-9. doi: 10.1002/ana.24672.

PMID:
27129429
19.

Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals.

Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague S, Xiong C, Grant EA, Campbell A, Ott BR, Holtzman DM, Benzinger TL, Fagan AM, Carr DB, Morris JC.

Alzheimer Dis Assoc Disord. 2016 Apr 28. [Epub ahead of print]

PMID:
27128959
20.

Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.

Ingber AP, Hassenstab J, Fagan AM, Benzinger TL, Grant EA, Holtzman DM, Morris JC, Roe CM.

J Alzheimers Dis. 2016;52(3):1055-64. doi: 10.3233/JAD-150478.

Items per page

Supplemental Content

Loading ...
Support Center